Navigation Links
MAP Pharmaceuticals to Present at the 2008 RBC Capital Markets Healthcare Conference
Date:12/3/2008

MOUNTAIN VIEW, Calif., Dec. 3 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that the company, will participate in a panel discussion titled "Adapting Specialty Pharma Strategy To Market Conditions" at the 2008 RBC Capital Markets Healthcare Conference on Wednesday, December 10, 2008, at 10:00 am (ET) in New York City.

A live webcast of the panel discussion will be available on the Investor Relations section of MAP Pharmaceuticals' website at http://www.mappharma.com. A replay will also be available within 24 hours for seven days following the presentation.

About MAP Pharmaceuticals, Inc.

MAP Pharmaceuticals is dedicated to developing and commercializing new therapies for children and adults suffering from chronic conditions that are not adequately treated by currently available medicines. The company has two product candidates in Phase 3 clinical trials. Unit Dose Budesonide is being developed for the potential treatment of pediatric asthma, and MAP0004 is being developed for the potential treatment of migraine. MAP Pharmaceuticals generates new pipeline opportunities by applying its proprietary drug particle and inhalation technologies to enhance the therapeutic benefits of proven drugs, while minimizing risk, by capitalizing on their known safety, efficacy and history.

Additional information about MAP Pharmaceuticals can be found at http://www.mappharma.com.


'/>"/>
SOURCE MAP Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. The Westaim Corporation requisitions meeting of shareholders of NUCRYST Pharmaceuticals to return capital to NUCRYST shareholders
2. Quark Pharmaceuticals to Present at the 20th Annual Piper Jaffray Health Care Conference
3. Transcept Pharmaceuticals to Participate on Drug Delivery Investor Panel
4. China West II Files Suit Against Genesis Pharmaceuticals and Capital Research Group Inc, Announces Conference Call Details
5. Watson Pharmaceuticals Receives FDA Final Approval for Generic Wellbutrin XL(R) 150 mg
6. Idenix Pharmaceuticals to Present at the PiperJaffray 20th Annual Health Care Conference
7. Peregrine Pharmaceuticals Awarded Broad New U.S. Patent for Anti-Viral Applications of Phospholipid-Targeting Antibodies
8. Arena Pharmaceuticals to Present at the Piper Jaffray 20th Annual Health Care Conference
9. Roche Signs Definitive Agreement to Acquire Memory Pharmaceuticals
10. Transcept Pharmaceuticals, Inc. to Present at the 20th Annual Piper Jaffray Health Care Conference
11. King Pharmaceuticals To Acquire Alpharma for Approximately $1.6 Billion
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2017)... ... May 26, 2017 , ... via seating ... mesh back 24/7 task chair specifically designed for clinical areas. Genie Copper Mesh ... to partner with Cupron® to provide customers with a game changing chair that ...
(Date:5/26/2017)... ... ... Rob Lowe acts as host and helps educate and inform the public using the ... can reconnect with America as it explores some of the best places to hike ... an inventive new place for a family vacation, and have discovered hiking. Many will ...
(Date:5/26/2017)... (PRWEB) , ... May 26, 2017 , ... “Just What Happened in the Garden of ... in the Garden of Eden” is the creation of published author, Penelope Colt, mother, trader, ... her family moved to NYC when she was three. At six, they moved to ...
(Date:5/24/2017)... ... May 24, 2017 , ... Dr. Alan I. Benvenisty, MD is ... York City. He is known for his distinguished expertise and experience in the diagnosis ... holds sub-specialty training in treating renovascular disease and aortic aneurysm . He is ...
(Date:5/24/2017)... OH (PRWEB) , ... May 24, 2017 , ... Patients ... in Cortland, OH, can now meet with Dr. Joseph Bedich for a consultation, with ... while simultaneously improving their oral health and functionality. , Dr. Bedich offers ...
Breaking Medicine News(10 mins):
(Date:5/26/2017)... 25, 2017  In response to the opioid epidemic ... Relief is working with Pfizer to make up to ... cost to community health centers, free and charitable clinics, ... "Pfizer has a long-standing commitment to improving ... patient safety through educational activities," said Caroline Roan ...
(Date:5/22/2017)... 2017  As the specialty pharmacy industry and ... make the revolutionary shift from volume-based to value-based ... positive patient outcomes and shaping the future of ... away from clinical trials and toward data that ... drug therapy utilization in precise patient populations. Therigy ...
(Date:5/15/2017)... May 15, 2017 Enterin Inc., a privately-held CNS ... developing novel compounds to treat Parkinson,s disease (PD), has enrolled ... a Phase 1/2a randomized, controlled, multicenter study involving patients with ... enroll 50 patients over a 9-to-12-month period. The first stage ... patients with PD. Participating sites include Denver ...
Breaking Medicine Technology: